Treatment and Prognosis of Patients With Chronic HBV Infection
Recruiting · NCT05392387 · Observational (researchers observe without assigning treatment) · Lead sponsor: Xiangya Hospital of Central South University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.
Who can take part
Inclusion criteria
- patients with evidence of chronic HBV infection
Exclusion criteria
- chronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.
Where it is running
1 location listed.
- Department of Infectious Disease, Xiangya Hospital, Central South University - Changsha, Hunan, China